[go: up one dir, main page]

WO1999058691A3 - (alpha)-l-iduronidase recombinee, procedes de production et de purification de celle-ci et methodes de traitement de maladies dues a des deficits en celle-ci - Google Patents

(alpha)-l-iduronidase recombinee, procedes de production et de purification de celle-ci et methodes de traitement de maladies dues a des deficits en celle-ci Download PDF

Info

Publication number
WO1999058691A3
WO1999058691A3 PCT/US1999/010102 US9910102W WO9958691A3 WO 1999058691 A3 WO1999058691 A3 WO 1999058691A3 US 9910102 W US9910102 W US 9910102W WO 9958691 A3 WO9958691 A3 WO 9958691A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
iduronidase
recombinant
purifying
deficiencies
Prior art date
Application number
PCT/US1999/010102
Other languages
English (en)
Other versions
WO1999058691A2 (fr
Inventor
Emil D Kakkis
Becky Tanamachi
Original Assignee
Harbor Ucla
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harbor Ucla filed Critical Harbor Ucla
Priority to CA002328518A priority Critical patent/CA2328518A1/fr
Priority to AU40724/99A priority patent/AU4072499A/en
Priority to JP2000548482A priority patent/JP2002514429A/ja
Priority to EP99924155A priority patent/EP1078075A2/fr
Priority to BR9910323-0A priority patent/BR9910323A/pt
Priority to IL13961699A priority patent/IL139616A0/xx
Publication of WO1999058691A2 publication Critical patent/WO1999058691A2/fr
Publication of WO1999058691A3 publication Critical patent/WO1999058691A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01076—L-Iduronidase (3.2.1.76)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une α-L-iduronidase, des fragments et des mutants biologiquement actifs de celle-ci, des procédés de production et de purification de cette enzyme, ainsi que des méthodes de traitement de certaines affections génétiques comprenant un déficit en α-L-iduronidase et la mucopolysaccharidose I (MPS I).
PCT/US1999/010102 1998-05-13 1999-05-07 (alpha)-l-iduronidase recombinee, procedes de production et de purification de celle-ci et methodes de traitement de maladies dues a des deficits en celle-ci WO1999058691A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002328518A CA2328518A1 (fr) 1998-05-13 1999-05-07 (alpha)-l-iduronidase recombinee, procedes de production et de purification de celle-ci et methodes de traitement de maladies dues a des deficits en celle-ci
AU40724/99A AU4072499A (en) 1998-05-13 1999-05-07 Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
JP2000548482A JP2002514429A (ja) 1998-05-13 1999-05-07 組換えα−Ｌ−イズロニダーゼ、その生成及び精製方法及びその欠損により引き起こされる疾病の治療方法
EP99924155A EP1078075A2 (fr) 1998-05-13 1999-05-07 (alpha)-l-iduronidase recombinee, procedes de production et de purification de celle-ci et methodes de traitement de maladies dues a des deficits en celle-ci
BR9910323-0A BR9910323A (pt) 1998-05-13 1999-05-07 Alfa-l-iduronidase recombinante, métodos para produção e purificação da mesma e métodos para tratamento de doenças ocasionadas deficiência da mesma
IL13961699A IL139616A0 (en) 1998-05-13 1999-05-07 Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating, diseases caused by deficiencies thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US7820998A 1998-05-13 1998-05-13
US09/078,209 1998-05-13
US17097798A 1998-10-13 1998-10-13
US09/170,977 1998-10-13

Publications (2)

Publication Number Publication Date
WO1999058691A2 WO1999058691A2 (fr) 1999-11-18
WO1999058691A3 true WO1999058691A3 (fr) 2000-02-17

Family

ID=26760239

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/010102 WO1999058691A2 (fr) 1998-05-13 1999-05-07 (alpha)-l-iduronidase recombinee, procedes de production et de purification de celle-ci et methodes de traitement de maladies dues a des deficits en celle-ci

Country Status (8)

Country Link
EP (1) EP1078075A2 (fr)
JP (1) JP2002514429A (fr)
CN (1) CN1300323A (fr)
AU (1) AU4072499A (fr)
BR (1) BR9910323A (fr)
CA (1) CA2328518A1 (fr)
IL (1) IL139616A0 (fr)
WO (1) WO1999058691A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426208B1 (en) * 1999-11-12 2002-07-30 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
US6585971B1 (en) 1999-11-12 2003-07-01 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof
US6569661B1 (en) 1999-11-12 2003-05-27 Biomarin Pharmaceutical Inc. Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
ES2599401T3 (es) 2000-07-18 2017-02-01 Duke University Tratamiento de glucogenosis de tipo II
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
WO2012054723A2 (fr) * 2010-10-22 2012-04-26 Opko Curna Llc Traitement de maladies associées à l'alpha-l-iduronidase (idua) par inhibition du transcrit antisens endogène de idua
CN103487414A (zh) * 2012-06-14 2014-01-01 北京和信非凡生物技术有限公司 一种α-L-艾杜糖醛酸酶活性检测方法、底物和试剂
DK2984166T3 (da) * 2013-03-15 2020-07-20 Univ Pennsylvania Sammensætninger til behandling af mpsi
EP3411488A1 (fr) 2016-02-03 2018-12-12 The Trustees Of The University Of Pennsylvania Thérapie génique pour traiter la mucopolysaccharidose de type i
US20190358303A1 (en) * 2017-01-31 2019-11-28 Regenxbio Inc. Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idua)
US11890329B2 (en) 2017-07-06 2024-02-06 The Trustees Of The University Of Pennsylvania AAV9-mediated gene therapy for treating mucopolysaccharidosis type I
CN107699590A (zh) * 2017-10-13 2018-02-16 成都中医药大学 一种制备重组人α‑L‑艾杜糖醛酸酶的方法
CN115109790A (zh) * 2021-03-23 2022-09-27 北京据德医药科技有限公司 一种重组a-L-艾杜糖醛酸普酶及其制备方法
CN114181318B (zh) * 2021-11-08 2023-08-01 四川大学 一种组织特异性表达穿透血脑屏障的idua融合蛋白的重组腺相关病毒及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010244A1 (fr) * 1991-11-14 1993-05-27 Women's And Children's Hospital α-L IDURONIDASE SYNTHETIQUE ET SEQUENCES GENETIQUES LA CODANT
WO1997010353A1 (fr) * 1995-09-14 1997-03-20 Virginia Tech Intellectual Property, Inc. Production d'enzymes lysosomiales par des systemes d'expression vegetaux

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010244A1 (fr) * 1991-11-14 1993-05-27 Women's And Children's Hospital α-L IDURONIDASE SYNTHETIQUE ET SEQUENCES GENETIQUES LA CODANT
WO1997010353A1 (fr) * 1995-09-14 1997-03-20 Virginia Tech Intellectual Property, Inc. Production d'enzymes lysosomiales par des systemes d'expression vegetaux

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CLEMENTS P ET AL: "Human alpha-L-iduronidase. 1. Purification, monoclonal antibody production, native and subunit molecular mass", EUR J BIOCHEM, vol. 152, no. 1, 1 October 1985 (1985-10-01), pages 21 - 28, XP000857400 *
KAKKIS E ET AL: "Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I", BIOCHEM MOL MED, vol. 58, no. 2, August 1996 (1996-08-01), pages 156 - 167, XP000862844 *
KAKKIS E ET AL: "Overexpression of the human lysosomal enzyme alpha-L-iduronidase in Chinese hamster ovary cells", PROTEIN EXPR PURIF, vol. 5, no. 3, June 1994 (1994-06-01), pages 225 - 232, XP000857380 *
SHULL R ET AL: "Enzyme replacement in a canine model of Hurler syndrome", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 91, no. 26, 20 December 1994 (1994-12-20), pages 12937 - 12941, XP002125064 *
UNGER E ET AL: "Recombinant alpha-L-iduronidase: characterization of the purified enzyme and correction of mucopolysaccharidosis type I fibroblasts", BIOCHEM J, vol. 304, 15 November 1994 (1994-11-15), pages 43 - 49, XP000857388 *

Also Published As

Publication number Publication date
BR9910323A (pt) 2001-01-30
JP2002514429A (ja) 2002-05-21
CA2328518A1 (fr) 1999-11-18
IL139616A0 (en) 2002-02-10
WO1999058691A2 (fr) 1999-11-18
CN1300323A (zh) 2001-06-20
EP1078075A2 (fr) 2001-02-28
AU4072499A (en) 1999-11-29

Similar Documents

Publication Publication Date Title
CA2391098A1 (fr) .alpha.-iduronidase recombinante, procede de preparation et de purification de celle-ci et methodes de traitement des maladies causees par des deficiences de celle-ci
WO1999058691A3 (fr) (alpha)-l-iduronidase recombinee, procedes de production et de purification de celle-ci et methodes de traitement de maladies dues a des deficits en celle-ci
WO2002038775A3 (fr) METHODES PERMETTANT DE PRODUIRE ET DE PURIFIER UNE α-L-IDURONIDASE RECOMBINEE
EP2169076A3 (fr) Enzymes dotées d'une activité alpha amylase et leurs procédés d'utilisation
PL365683A1 (en) Selected fused pyrrolocarbazoles
DE69731955D1 (de) Kombination von saurer protease-enzyme und saure puffers und ihre verwendung
WO2004018655A3 (fr) Compositions et methodes de culture de cellules souches
IL181695A0 (en) Methods for cultivating cells and propagating viruses
EP0869174A3 (fr) Procédé pour clonage et production de l'endonucléase de restriction Spel
WO2003035679A3 (fr) Molecules
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
AU4837499A (en) Method of treating disorders by modulating the interaction of natural killer receptors on t cells with their respective ligands
WO2004043373A3 (fr) Precurseur n-acetylgalactosamine-4-sulfatase, methodes de traitement au moyen dudit enzyme et procedes de production et de purification dudit enzyme
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
WO2003056897A3 (fr) Beta-glucocerebrosidase d'acide fortement phosphoryle et methodes de traitement de la maladie de gaucher
ES2138939A1 (es) Pomada para quemaduras.
WO2000061727A3 (fr) Production de procarboxypeptidase b pancreatique, de ses isoformes et muteines et leur utilisation
EP0931835A3 (fr) Procédé de clonage et de production de l'endonucléase de restriction PmeI
AU2002251788A1 (en) Novel compounds and uses thereof
WO1998046768A3 (fr) Esterase d'acide phenolique et utilisation de cette derniere
MXPA02011162A (es) Proteina cln2 recombinante de humano y metodos para su reduccion y uso.
WO2001019989A3 (fr) Procede de preparation et de purification d'une proteine d'endostatine¿tm?
TW370564B (en) The process for producing rice Cn/Zn-superoxide dismutase
AU2003261230A1 (en) Apolipoprotein e stable folding intermediate and methods of use thereof
GB9818650D0 (en) Therapeutic compounds and methods of making and using the same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99806064.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 1999924155

Country of ref document: EP

Ref document number: 40724/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2000/00598/MU

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2328518

Country of ref document: CA

Ref document number: 2328518

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 139616

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2000 548482

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/011137

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 1999924155

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999924155

Country of ref document: EP